Brokerages Set Pyxis Oncology, Inc. (NASDAQ:PYXS) PT at $6.86

Pyxis Oncology, Inc. (NASDAQ:PYXS) has received a consensus rating of “Moderate Buy” from the nine analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $6.8571.

A number of equities analysts recently issued reports on the stock. Wall Street Zen lowered shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings downgraded shares of Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Leerink Partners cut their price objective on shares of Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating for the company in a research report on Thursday, July 2nd. Finally, Wedbush assumed coverage on shares of Pyxis Oncology in a research note on Tuesday, May 5th. They issued an “outperform” rating and a $6.00 target price for the company.

Institutional Trading of Pyxis Oncology

Institutional investors have recently modified their holdings of the company. Atle Fund Management AB acquired a new position in shares of Pyxis Oncology in the fourth quarter valued at $710,000. 683 Capital Management LLC boosted its stake in Pyxis Oncology by 69.9% during the fourth quarter. 683 Capital Management LLC now owns 891,910 shares of the company’s stock worth $1,026,000 after buying an additional 366,910 shares in the last quarter. Avanza Fonder AB bought a new stake in Pyxis Oncology in the 4th quarter valued at $31,000. Barclays PLC increased its holdings in Pyxis Oncology by 1,939.3% in the 4th quarter. Barclays PLC now owns 60,385 shares of the company’s stock valued at $69,000 after buying an additional 57,424 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in shares of Pyxis Oncology by 37.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 50,066 shares of the company’s stock valued at $58,000 after buying an additional 13,550 shares in the last quarter. Institutional investors and hedge funds own 39.07% of the company’s stock.

Pyxis Oncology Stock Up 11.5%

Shares of NASDAQ:PYXS opened at $2.91 on Tuesday. The company has a market cap of $184.35 million, a price-to-earnings ratio of -2.22 and a beta of 1.30. The business has a 50 day moving average price of $2.18 and a 200 day moving average price of $1.83. Pyxis Oncology has a twelve month low of $0.97 and a twelve month high of $5.55.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). Analysts anticipate that Pyxis Oncology will post -1.19 EPS for the current year.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.